Do we need controlled attenuation parameter adjustment for fibrosis estimation in nonalcoholic fatty liver disease
Thomas Karlas1, Sebastian Beer1,2, Jonas Babel1
1Division of Gastroenterology and Rheumatology, University Hospital Leipzig, Leipzig, Germany.
Hepatology (Baltimore, Md.)
|January 20, 2017
Abstract
No abstract available in PubMed .
More Related Videos
Related Concept Videos
Ultrasound II: Endoscopic Ultrasound and FibroScan
935
Endoscopic Ultrasound (EUS) and FibroScan are valuable diagnostic tools in gastroenterology and hepatology, each with specific applications and techniques.
Endoscopic Ultrasound (EUS):
Endoscopic Ultrasound (EUS):
935
Effect of Hepatic Disease on Pharmacokinetics: Pathophysiologic Assessment and Liver Function Test
245
In clinical practice, the direct measurement of hepatic blood flow to evaluate liver function presents significant challenges due to the intricate and specialized nature of the necessary techniques. Consequently, healthcare professionals often rely on empirical estimates derived from thorough patient examinations and liver function tests to gauge liver health. Among the tools at their disposal, the Child–Pugh and MELD scoring systems stand out for their ability to categorize and assess...
245
Effect of Hepatic Disease on Pharmacokinetics: Drug Dosing and Hepatic Blood Flow
305
Chronic liver disease significantly impacts drug metabolism due to alterations in hepatic blood flow and enzyme accessibility. This disruption affects the body's pharmacokinetics—the movement and processing of drugs within the system. Key enzymes crucial for metabolizing medications become less accessible, changing how drugs are processed and utilized. Furthermore, liver disease influences the synthesis of plasma proteins, such as albumin and globulins, which play critical roles in drug...
305


